Current Treatment Options in Allergy

, Volume 5, Issue 1, pp 41–51 | Cite as

Mast Cell Activation Syndromes and Environmental Exposures

  • David González-de-OlanoEmail author
  • Javier Domínguez-Ortega
  • Silvia Sánchez-García
Occupational Allergy (S Quirce and J Sastre, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Occupational Allergy

Opinion statement

Mast cell activation syndromes (MCAS) are an emerging entity that includes a heterogeneous group of diseases presenting with typical signs and symptoms secondary to the release of mast cell (MC) mediators. Triggering factors underlying the activation of mast cells show a wide variability, and episodes of MC-mediator release are usually triggered by idiopathic or by mixed causes, which makes avoidance recommendations difficult to devise. Sometimes, environmental or occupational exposures are responsible for MC activation. In this article, we review the main workplace environment eliciting factors described in MCAS and the current guidance on treatment.


Clonal Environmental Mast cell Mast cell activation syndrome Mastocytosis Occupational 



We thank Isabel Coman for her technical assistance with the revision of the English version of the manuscript.


This work was supported by a grant from the Sociedad Española Alergia e Inmunología Clínica 2014.

Compliance with ethical standards

Conflict of interest

David González-de-Olano declares that he has no conflict of interest. Javier Domínguez-Ortega declares that he has no conflict of interest. Silvia Sánchez-García declares that she has no conflict of interest.

Human and animal rights and informed consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: A consensus proposal. Int Arch Allergy Immunol. 2011;157(3):215–25.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: Proposed diagnostic criteria. J Allergy Clin Immunol. 2010;126(6):1099–104. e1094Google Scholar
  3. 3.
    Cowen T, Trigg P, Eady RA. Distribution of mast cells in human dermis: Development of a mapping technique. Br J Dermatol. 1979;100(6):635–40.CrossRefPubMedGoogle Scholar
  4. 4.
    Strobel S, Miller HR, Ferguson A. Human intestinal mucosal mast cells: Evaluation of fixation and staining techniques. J Clin Pathol. 1981;34(8):851–8.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Irani AM, Butrus SI, Tabbara KF, Schwartz LB. Human conjunctival mast cells: Distribution of mct and mctc in vernal conjunctivitis and giant papillary conjunctivitis. J Allergy Clin Immunol. 1990;86(1):34–40.CrossRefPubMedGoogle Scholar
  6. 6.
    Baddeley SM, Bacon AS, JI MG, Lightman SL, Holgate ST, Roche WR. Mast cell distribution and neutral protease expression in acute and chronic allergic conjunctivitis. Clin Exp Allergy. 1995;25(1):41–50.CrossRefPubMedGoogle Scholar
  7. 7.
    Schulman ES, DW MG Jr, Peters SP, Schleimer RP, Newball HH, Lichtenstein LM. Human lung mast cells: Purification and characterization. J Immunol. 1982;129(6):2662–7.PubMedGoogle Scholar
  8. 8.
    Gonzalez-de-Olano D, Alvarez-Twose I. Insights in anaphylaxis and clonal mast cell disorders. Front Immunol. 2017;8:792.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Valent P, Akin C, Hartmann K, Nilsson G, Reiter A, Hermine O, et al. Advances in the classification and treatment of mastocytosis: Current status and outlook toward the future. Cancer Res. 2017;77(6):1261–70.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405.CrossRefPubMedGoogle Scholar
  11. 11.
    Escribano L, Garcia-Montero A, Sanchez-Muñoz L, Teodosio C, Alvarez-Twose I, Jara-Acevedo M. Diagnosis of adult mastocytosis: Role for bone marrow analysis. In: Kottke-Marchant K, Davis B, editors. Laboratory hematology practice. London: Wiley-Blackwell; 2012. p. 388–98.CrossRefGoogle Scholar
  12. 12.
    Gonzalez-de-Olano D, Alvarez-Twose I, Vega A, Orfao A, Escribano L. Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis. Immunotherapy. 2011;3(5):637–51.CrossRefPubMedGoogle Scholar
  13. 13.
    Escribano L, Orfao A, Villarrubia J, Martin F, Madruga JI, Cuevas M, et al. Sequential immunophenotypic analysis of mast cells in a case of systemic mast cell disease evolving to a mast cell leukemia. Cytometry. 1997;30(2):98–102.CrossRefPubMedGoogle Scholar
  14. 14.
    • Gonzalez-de-Olano D, Matito A, Orfao A, Escribano L. Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes. F1000Res. 2016;5:2666. Complete and easy to read review of mast cell activation syndromes and their current recommended management.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    •• Alvarez-Twose I, Gonzalez de Olano D, Sanchez-Munoz L, Matito A, Esteban-Lopez MI, Vega A, et al. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol. 2010;125(6):1269–78. e1262. This is the first article that describes the clinical and biological characteristics of the clonal mast cell disorders, and helps differenciate with other types of MCD. Besides, a helpful screening tool that suggests clonality is provided.CrossRefPubMedGoogle Scholar
  16. 16.
    Alvarez-Twose I, Zanotti R, Gonzalez-de-Olano D, Bonadonna P, Vega A, Matito A, et al. Nonaggressive systemic mastocytosis (sm) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent sm. J Allergy Clin Immunol. 2014;133(2):520–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Sperr WR, Escribano L, Jordan JH, Schernthaner GH, Kundi M, Horny HP, et al. Morphologic properties of neoplastic mast cells: Delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res. 2001;25(7):529–36.CrossRefPubMedGoogle Scholar
  18. 18.
    Horny HP, Sillaber C, Menke D, Kaiserling E, Wehrmann M, Stehberger B, et al. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol. 1998;22(9):1132–40.CrossRefPubMedGoogle Scholar
  19. 19.
    Horny HP, Valent P. Diagnosis of mastocytosis: General histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res. 2001;25(7):543–51.CrossRefPubMedGoogle Scholar
  20. 20.
    Orfao A, Escribano L, Villarrubia J, Velasco JL, Cervero C, Ciudad J, et al. Flow cytometric analysis of mast cells from normal and pathological human bone marrow samples: Identification and enumeration. Am J Pathol. 1996;149(5):1493–9.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Escribano L, Diaz-Agustin B, Lopez A, Nunez Lopez R, Garcia-Montero A, Almeida J, et al. Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the spanish network on mastocytosis (rema). Cytometry B Clin Cytom. 2004;58(1):1–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Escribano L, Orfao A, Diaz-Agustin B, Villarrubia J, Cervero C, Lopez A, et al. Indolent systemic mast cell disease in adults: Immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood. 1998;91(8):2731–6.PubMedGoogle Scholar
  23. 23.
    Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A, et al. Kit mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: A prospective study of the spanish network on mastocytosis (rema) in a series of 113 patients. Blood. 2006;108(7):2366–72.CrossRefPubMedGoogle Scholar
  24. 24.
    Sotlar K, Escribano L, Landt O, Mohrle S, Herrero S, Torrelo A, et al. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol. 2003;162(3):737–46.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Alvarez-Twose I, Gonzalez-de-Olano D, Sanchez-Munoz L, Matito A, Jara-Acevedo M, Teodosio C, et al. Validation of the rema score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms. Int Arch Allergy Immunol. 2011;157(3):275–80.CrossRefPubMedGoogle Scholar
  26. 26.
    Valent P, Escribano L, Broesby-Olsen S, Hartmann K, Grattan C, Brockow K, et al. Proposed diagnostic algorithm for patients with suspected mastocytosis: A proposal of the european competence network on mastocytosis. Allergy. 2014;69(10):1267–74.CrossRefPubMedGoogle Scholar
  27. 27.
    Valent P. Risk factors and management of severe life-threatening anaphylaxis in patients with clonal mast cell disorders. Clin Exp Allergy. 2014;44(7):914–20.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Alvarez-Twose I, Matito A, Sanchez-Muñoz L, Morgado JM, Escribano L. Management of adult mastocytosis. Expert Opin Orphan Drugs. 2014;2(4):16.Google Scholar
  29. 29.
    Matito A, Alvarez-Twose I, Morgado JM, Sanchez-Munoz L, Orfao A, Escribano L. Anaphylaxis as a clinical manifestation of clonal mast cell disorders. Curr Allergy Asthma Rep. 2014;14(8):450.CrossRefPubMedGoogle Scholar
  30. 30.
    Jennings S, Russell N, Jennings B, Slee V, Sterling L, Castells M, et al. The mastocytosis society survey on mast cell disorders: Patient experiences and perceptions. J Allergy Clin Immunol Pract. 2014;2(1):70–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Fried AJ, Akin C. Primary mast cell disorders in children. Curr Allergy Asthma Rep. 2013;13(6):693–701.CrossRefPubMedGoogle Scholar
  32. 32.
    •• Siracusa A, Folletti I, Gerth van Wijk R, Jeebhay MF, Moscato G, Quirce S, et al. Occupational anaphylaxis--an eaaci task force consensus statement. Allergy. 2015;70(2):141–52. This is a complete document assessing the main causes of anaphylaxis at the work place. If we recognized a possible occupation at risk of anaphylaxis, we could identify a potential risk for severe systemic reactions in a worker with mastocytosis.CrossRefPubMedGoogle Scholar
  33. 33.
    •• Gulen T, Ljung C, Nilsson G, Akin C. Risk factor analysis of anaphylactic reactions in patients with systemic mastocytosis. J Allergy Clin Immunol Pract. 2017;5(5):1248–55. This article provides a risk analysis model, offering a simple method of identifying patients with mastocytosis at high risk of anaphylaxis.CrossRefPubMedGoogle Scholar
  34. 34.
    Turner PJ, Jerschow E, Umasunthar T, Lin R, Campbell DE, Boyle RJ. Fatal anaphylaxis: Mortality rate and risk factors. J Allergy Clin Immunol Pract. 2017;5(5):1169–78.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Bonadonna P, Bonifacio M, Lombardo C, Zanotti R. Hymenoptera allergy and mast cell activation syndromes. Curr Allergy Asthma Rep. 2016;16(1):5.CrossRefPubMedGoogle Scholar
  36. 36.
    Bonadonna P, Lombardo C, Zanotti R. Mastocytosis and allergic diseases. J Investig Allergol Clin Immunol. 2014;24(5):288–97. quiz 283 p preceding 297Google Scholar
  37. 37.
    Gonzalez de Olano D, de la Hoz Caballer B, Nunez Lopez R, Sanchez Munoz L, Cuevas Agustin M, Dieguez MC, et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in spain: A study of the spanish network on mastocytosis (rema). Clin Exp Allergy. 2007;37(10):1547–55.PubMedGoogle Scholar
  38. 38.
    Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: A study on history, clinical features and risk factors in 120 patients. Allergy. 2008;63(2):226–32.CrossRefPubMedGoogle Scholar
  39. 39.
    van der Weide HY, van Westerloo DJ, van den Bergh WM. Critical care management of systemic mastocytosis: When every wasp is a killer bee. Crit Care. 2015;19:238.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    MAW H, MJA R, van Laar JAM, Dalm V, Verburg M, Pasmans S, et al. Systemic mastocytosis: A cohort study on clinical characteristics of 136 patients in a large tertiary centre. Eur J Intern Med. 2016;30:25–30.CrossRefGoogle Scholar
  41. 41.
    Quirce S, Fiandor A. How should occupational anaphylaxis be investigated and managed? Curr Opin Allergy Clin Immunol. 2016;16(2):86–92.CrossRefPubMedGoogle Scholar
  42. 42.
    Akin C. Anaphylaxis and mast cell disease: What is the risk? Curr Allergy Asthma Rep. 2010;10(1):34–8.CrossRefPubMedGoogle Scholar
  43. 43.
    Asawa A, Simpson KH, Bonds RS. Ketotifen use in a patient with fire ant hypersensitivity and mast cell activation syndrome. Ann Allergy Asthma Immunol. 2015;114(6):443–6.CrossRefPubMedGoogle Scholar
  44. 44.
    Richter AG, Nightingale P, Huissoon AP, Krishna MT. Risk factors for systemic reactions to bee venom in british beekeepers. Ann Allergy Asthma Immunol. 2011;106(2):159–63.CrossRefPubMedGoogle Scholar
  45. 45.
    Boyle RJ, Dickson R, Hockenhull J, Cherry MG, Elremeli M. Immunotherapy for hymenoptera venom allergy: Too expensive for european health care? Allergy. 2013;68(10):1341–2.CrossRefPubMedGoogle Scholar
  46. 46.
    Lieberman P, Schwartz LB. Anaphylactic reaction to white-faced hornet sting and elevated baseline (asymptomatic) serum tryptase. J Allergy Clin Immunol Pract. 2013;1(3):315.CrossRefPubMedGoogle Scholar
  47. 47.
    Cruz S, Vega A, Fernandez S, Marques L, Baltasar M, Alonso A, et al. Report from the hymenoptera committee of the spanish society of allergology and clinical immunology: Immunotherapy with bumblebee venom. J Investig Allergol Clin Immunol. 2012;22(5):377–8.PubMedGoogle Scholar
  48. 48.
    Reiter N, Reiter M, Altrichter S, Becker S, Kristensen T, Broesby-Olsen S, et al. Anaphylaxis caused by mosquito allergy in systemic mastocytosis. Lancet. 2013;382(9901):1380.CrossRefPubMedGoogle Scholar
  49. 49.
    • Morales-Cabeza C, Prieto-Garcia A, Acero S, Bartolome-Zavala B, Morgado JM, Matito A, et al. Systemic mastocytosis presenting as occupational ige-mediated anaphylaxis to pine processionary caterpillar. Ann Allergy Asthma Immunol. 2016;117(3):333–4. e331. A very well-described case of occupational anaphylaxis due to the contact to an insect exclusively at the work place, and the ulterior allergologic work-up.CrossRefPubMedGoogle Scholar
  50. 50.
    Meseguer Arce J, Villajos IM, Iraola V, Carnes J, Fernandez Caldas E. Occupational allergy to aquarium fish food: Red midge larva, freshwater shrimp, and earthworm. A clinical and immunological study. J Investig Allergol Clin Immunol. 2013;23(7):462–70.PubMedGoogle Scholar
  51. 51.
    Zhang D, Spielmann A, Wang L, Ding G, Huang F, Gu Q, et al. Mast-cell degranulation induced by physical stimuli involves the activation of transient-receptor-potential channel trpv2. Physiol Res. 2012;61(1):113–24.PubMedGoogle Scholar
  52. 52.
    Gulen T, Hagglund H, Dahlen B, Nilsson G. High prevalence of anaphylaxis in patients with systemic mastocytosis - a single-centre experience. Clin Exp Allergy. 2014;44(1):121–9.CrossRefPubMedGoogle Scholar
  53. 53.
    Broesby-Olsen S, Vestergaard H, Mortz CG, Jensen B, Havelund T, Hermann AP, et al. Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations. Allergy. 2017.
  54. 54.
    Antolin-Amerigo D, Ruiz-Leon B, Boni E, Alfaya-Arias T, Alvarez-Mon M, Barbarroja-Escudero J, et al. Component-resolved diagnosis in hymenoptera allergy. Allergol Immunopathol (Madr). 2017.
  55. 55.
    Fricker M, Helbling A, Schwartz L, Muller U. Hymenoptera sting anaphylaxis and urticaria pigmentosa: Clinical findings and results of venom immunotherapy in ten patients. J Allergy Clin Immunol. 1997;100(1):11–5.CrossRefPubMedGoogle Scholar
  56. 56.
    Haeberli G, Bronnimann M, Hunziker T, Muller U. Elevated basal serum tryptase and hymenoptera venom allergy: Relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy. 2003;33(9):1216–20.CrossRefPubMedGoogle Scholar
  57. 57.
    Gonzalez de Olano D, Alvarez-Twose I, Esteban-Lopez MI, Sanchez-Munoz L, de Durana MD, Vega A, et al. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with hymenoptera venom anaphylaxis. J Allergy Clin Immunol. 2008;121(2):519–26.CrossRefPubMedGoogle Scholar
  58. 58.
    Bonadonna P, Gonzalez-de-Olano D, Zanotti R, Riccio A, De Ferrari L, Lombardo C, et al. Venom immunotherapy in patients with clonal mast cell disorders: Efficacy, safety, and practical considerations. J Allergy Clin Immunol Pract. 2013;1(5):474–8.CrossRefPubMedGoogle Scholar
  59. 59.
    Bonifazi F, Jutel M, Bilo BM, Birnbaum J, Muller U. Prevention and treatment of hymenoptera venom allergy: Guidelines for clinical practice. Allergy. 2005;60(12):1459–70.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • David González-de-Olano
    • 1
    Email author
  • Javier Domínguez-Ortega
    • 2
  • Silvia Sánchez-García
    • 3
  1. 1.Department of AllergyHospital Universitario Ramón y CajalMadridSpain
  2. 2.Department of AllergyHospital La Paz Institute for Health Research (IdiPAZ), and CIBER de Enfermedades Respiratorias, CIBERESMadridSpain
  3. 3.Department of AllergyHospital Infantil Universitario Niño Jesús and IIS-La PrincesaMadridSpain

Personalised recommendations